We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Epizyme (EPZM) This Earnings Season?
Read MoreHide Full Article
Epizyme, Inc. is expected to report fourth-quarter 2017 results on Mar 8, after the closing bell.
Last quarter, the company delivered a positive earnings surprise of 3.08%. In fact, its track record has been solid, with Epizyme surpassing expectations in each of the trailing four quarters, recording an average positive surprise of 8.68%.
Notably, Epizyme’s shares have returned 30.7% over a year as against the industry’s decline of 2.6%.
Let’s see how things are shaping up for this quarter.
Factors Influencing This Quarter
Epizyme has made significant progress with its lead candidate, tazemetostat (an EZH2 inhibitor), for the treatment of multiple types of hematological malignancies and genetically defined solid tumors.
Epizyme is conducting a broad clinical development program for tazemetostat as both a monotherapy and combination treatment in relapsed/refractory and first-line non-Hodgkin lymphoma (“NHL”). The company expects to submit a new drug application (“NDA”) for the NHL in 2019.
The company is also exploring tazemetostat to increase the clinical activity of immuno-oncology therapies by combining an anti-PD 1 or PDL-1 agent. Under its collaboration with Roche (RHHBY - Free Report) , the company is evaluating tazemetostat, in combination with anti-PD-L1 cancer immunotherapy, Tecentriq, for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (“DLBCL”)to determine the recommended phase II dose and advance the study.
The company is also evaluating tazemetostat as a treatment for adults with mesothelioma characterized by BAP1 loss-of-function and expects to report data from phase II study for the same in 2018.
Epizyme’s second pipeline candidate, pinometostat is being evaluated in a phase I dose-escalation study on pediatric patients suffering from an acute leukemia with genetic alterations of the MLL gene (MLL-r). Epizyme has an agreement with Celgene for the discovery, development and commercialization of small-molecule HMT inhibitors including pinometostat in ex-United States’ markets.
Epizyme had $307.2 million of cash, cash equivalents and marketable securities as of Sep 30, 2017 and expects that it will be sufficient to fund its planned operations at least till third-quarter 2019.
Earnings Whispers
Our proven model does not conclusively show an earnings beat for Epizyme this quarter. This is because a stock needs to have both — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — for this to happen. Unfortunately that is not the case here, as you will see below.
Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -0.40%. The Zacks Consensus estimate for the quarter’s earnings is pegged at a loss of 56 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Epizyme has a Zacks Rank #3. This when combined with negative ESP makes surprise prediction difficult.
Conversely, we caution against Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Atara Biotherapeutics (ATRA - Free Report) is expected to release fourth-quarter 2017 results on Mar 8. The company has an Earnings ESP of +7.42% and a Zacks Rank #3.
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
What's in Store for Epizyme (EPZM) This Earnings Season?
Epizyme, Inc. is expected to report fourth-quarter 2017 results on Mar 8, after the closing bell.
Last quarter, the company delivered a positive earnings surprise of 3.08%. In fact, its track record has been solid, with Epizyme surpassing expectations in each of the trailing four quarters, recording an average positive surprise of 8.68%.
Notably, Epizyme’s shares have returned 30.7% over a year as against the industry’s decline of 2.6%.
Let’s see how things are shaping up for this quarter.
Factors Influencing This Quarter
Epizyme has made significant progress with its lead candidate, tazemetostat (an EZH2 inhibitor), for the treatment of multiple types of hematological malignancies and genetically defined solid tumors.
Epizyme is conducting a broad clinical development program for tazemetostat as both a monotherapy and combination treatment in relapsed/refractory and first-line non-Hodgkin lymphoma (“NHL”). The company expects to submit a new drug application (“NDA”) for the NHL in 2019.
The company is also exploring tazemetostat to increase the clinical activity of immuno-oncology therapies by combining an anti-PD 1 or PDL-1 agent. Under its collaboration with Roche (RHHBY - Free Report) , the company is evaluating tazemetostat, in combination with anti-PD-L1 cancer immunotherapy, Tecentriq, for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (“DLBCL”)to determine the recommended phase II dose and advance the study.
The company is also evaluating tazemetostat as a treatment for adults with mesothelioma characterized by BAP1 loss-of-function and expects to report data from phase II study for the same in 2018.
Epizyme’s second pipeline candidate, pinometostat is being evaluated in a phase I dose-escalation study on pediatric patients suffering from an acute leukemia with genetic alterations of the MLL gene (MLL-r). Epizyme has an agreement with Celgene for the discovery, development and commercialization of small-molecule HMT inhibitors including pinometostat in ex-United States’ markets.
Epizyme had $307.2 million of cash, cash equivalents and marketable securities as of Sep 30, 2017 and expects that it will be sufficient to fund its planned operations at least till third-quarter 2019.
Earnings Whispers
Our proven model does not conclusively show an earnings beat for Epizyme this quarter. This is because a stock needs to have both — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — for this to happen. Unfortunately that is not the case here, as you will see below.
Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -0.40%. The Zacks Consensus estimate for the quarter’s earnings is pegged at a loss of 56 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Epizyme has a Zacks Rank #3. This when combined with negative ESP makes surprise prediction difficult.
Conversely, we caution against Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Epizyme, Inc. Price and EPS Surprise
Epizyme, Inc. Price and EPS Surprise | Epizyme, Inc. Quote
Stocks to Consider
Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Gemphire Therapeutics is expected to release fourth-quarter 2017 results on Mar 21. The company has an Earnings ESP of +8.01% and a Zacks Rank #2. You can seethe complete list of today’s Zacks #1 Rank stocks here.
Atara Biotherapeutics (ATRA - Free Report) is expected to release fourth-quarter 2017 results on Mar 8. The company has an Earnings ESP of +7.42% and a Zacks Rank #3.
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2018 today >>